Bipolar Patients and Bullous Pemphigoid After Risperidone Long-Acting Injectable: A Case Report and Literature Review
October 2021
in “
Brain Sciences
”
Studysummary This review hypothesizes that risperidone long-acting injectable may be linked to bullous pemphigoid in a bipolar patient, though current studies report mixed results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document is a case report and literature review exploring the occurrence of Bullous Pemphigoid (BP), a skin condition, in bipolar patients after long-term use of Risperidone Long-Acting Injectable (RLAI). The case study involves a 58-year-old patient who developed BP after 2 years of RLAI treatment. The literature review suggests a potential association between RLAI and BP, but the exact mechanism is unclear. The document also discusses the hypothesis that neurodegeneration or neuroinflammation might lead to a cross-reactive immune response between neural and cutaneous antigens, contributing to self-tolerance failure. The document concludes that BP comorbid with bipolar disorder could represent a serious health risk and affect patients’ physical and psychosocial quality of life, and clinicians should consider BP as a possible adverse effect of psychotropic medications.
